Folgen
Robert Liebner
Robert Liebner
Zugehörigkeit unbekannt
Bestätigte E-Mail-Adresse bei sanofi.com
Titel
Zitiert von
Zitiert von
Jahr
Protein HESylation for half-life extension: synthesis, characterization and pharmacokinetics of HESylated anakinra
R Liebner, R Mathaes, M Meyer, T Hey, G Winter, A Besheer
European Journal of Pharmaceutics and Biopharmaceutics 87 (2), 378-385, 2014
902014
Head to head comparison of the formulation and stability of concentrated solutions of HESylated versus PEGylated anakinra
R Liebner, M Meyer, T Hey, G Winter, A Besheer
Journal of Pharmaceutical Sciences 104 (2), 515-526, 2015
322015
Challenges for PEGylated proteins and alternative half-life extension technologies based on biodegradable polymers
A Besheer, R Liebner, M Meyer, G Winter
Tailored polymer architectures for pharmaceutical and biomedical …, 2013
192013
Freeze-drying of HESylated IFNα-2b: Effect of HESylation on storage stability in comparison to PEGylation
R Liebner, S Bergmann, T Hey, G Winter, A Besheer
International Journal of Pharmaceutics 495 (1), 608-611, 2015
102015
Tailored Polymer Architectures for Pharmaceutical and Biomedical Applications; Scholz, C., Kressler, J., Eds
A Besheer, R Liebner, M Meyer, G Winter
ACS Symposium Series 1135, 215, 0
4
Formulation of PEGylated and HESylated biopharmaceuticals
R Liebner
lmu, 2015
2015
Chapter III–Highly concentrated formulations
R Liebner, M Meyer, T Hey, G Winter, A Besheer
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–7